Article

Exposure to valsartan products containing nitrosamine impurities in the US, Canada, and Denmark

2023-12-07

Abstract excerpt

<h4>ABSTRACT</h4> <h4>Background</h4> Following the mass recall of valsartan products with nitrosamine impurities in July 2018, the number of patients exposed to these valsartan products, the duration of exposure, and the potential for cancer remains unknown. Therefore, we assessed the extent and duration of use of valsartan products with a nitrosamine impurity in the US, Canada, and Denmark. <h4>Methods</h4> We c...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 36398610-2969-5d5d-b583-d0c63304a4f9
DOI: 10.1101/2023.12.05.23299542

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Exposure to valsartan products containing nitrosamine impurities in the US, Canada, and DenmarkDOI 10.1101/2023.12.05.23299542Read

Permitted daily exposure limits for noteworthy N-nitrosamines.Semantic proximity Read

Ranitidine use, N-Nitrosodimethylamine (NDMA) production and variations in cancer diagnosesSemantic proximity Read

Ames concordance with the in vivo transgenic rodent (TGR) gene mutation assay for NDSRIs and relative in vivo TGR potency with nitrosamines with robust dose-response carcinogenicity data.Semantic proximity Read

Mutagenicity and genotoxicity evaluation of 15 nitrosamine drug substance-related impurities in human TK6 cells.Semantic proximity Read

Chemical Analysis of Aerosol from ElfBar Elfa Pod System Vaping Products Compared with Cigarette Smoke and Regulatory Safety LimitsSemantic proximity Read

Per- and polyfluoroalkyl substances (PFAS) Regulatory Frameworks, Sources, Occurrence, Fate, and Exposure: Trend, Concern, and ImplicationSemantic proximity Read

Development and Validation of Analytical Methods for the Quantification and Identification of N-Nitroso Trimetazidine, a Nitrosamine Impurity, in Drug Substance and Drug Product.Semantic proximity Read

New Serious Safety Warnings of Targeted Anticancer Agents After Their Initial FDA ApprovalSemantic proximity Read

Frequency and component analysis of contaminants generated in preparation of anticancer agents using Closed system drug transfer devices (CSTDs)Semantic proximity Read

N-nitrosamine impurity risk assessment in pharmaceuticals: Utilizing In vivo mutation relative potency comparison to establish an acceptable intake for NTTP.Semantic proximity Read

Characterizing Adulterant and Polysubstance Use Research Priorities through Syringe Residue Analysis in KentuckySemantic proximity Read

Genotoxicity assessments of N-nitrosoethylisopropylamine (NEIPA) and N-nitrosodiisopropylamine (NDIPA) in the C57BL/6J mouse.Semantic proximity Read